Clearmind Medicine Inc. (NASDAQ: CMND) has filed a patent application with the Hong Kong Patent Office covering psychedelic compounds intended for the treatment of Post-Traumatic Stress Disorder and other mental health disorders, according to a company statement.

The Hong Kong filing is part of Clearmind's exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem. Under that agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum.

The company said the Hong Kong application adds to existing patent coverage in the United States, Europe, and other jurisdictions. Clearmind's intellectual property portfolio currently includes 19 patent families and 32 granted patents.

According to market data cited in the press release, the global PTSD treatment market was valued at approximately $18.5 billion in 2025 and is projected to reach $30.2 billion by 2035, reflecting a compound annual growth rate of 5.0%.

Clearmind is a clinical-stage biotechnology company focused on developing nonhallucinogenic, neuroplastogen-derived treatments for conditions including alcohol use disorder, addiction, and weight management. The company is headquartered in Vancouver, Canada.